Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth P Gregory

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|January 22, 2024
New standards of care for treatment of diffuse large B-cell lymphomaChathuri Abeyakoon, Gareth P Gregory
Journal of Personalized Medicine|May 5, 2021
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell LymphomasRoss Salvaris, Jeremy Ong, Gareth P Gregory
Asia-Pacific Journal of Clinical Oncology|April 15, 2020
A consensus statement on the use of biosimilar medicines in hematology in AustraliaGareth P Gregory, Christine Carrington, Chan Y Cheah, et al.
Internal Medicine Journal|December 20, 2021
Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceColm Keane, Nada Hamad, Allison Barraclough, et al.
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
Internal Medicine Journal|April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphomaMichael Dickinson, Nicole O'Leary, Nada Hamad, et al.
Ejhaem|August 21, 2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at RelapseMark Waltham, Jonathan Wong, Galina Polekhina, et al.
Research and Practice in Thrombosis and Haemostasis|September 1, 2020
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapyHiu Lam Agnes Yuen, Alison Slocombe, Vanessa Heron, et al.
Leukemia & Lymphoma|September 28, 2020
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapyMaciej Tatarczuch, Erin Paul, Michael Gilberston, et al.
British Journal of Haematology|May 16, 2026
Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practiceElizabeth Goodall, Jodie Palmer, Arina Martynchyk, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|January 22, 2024
New standards of care for treatment of diffuse large B-cell lymphomaChathuri Abeyakoon, Gareth P Gregory
Journal of Personalized Medicine|May 5, 2021
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell LymphomasRoss Salvaris, Jeremy Ong, Gareth P Gregory
Asia-Pacific Journal of Clinical Oncology|April 15, 2020
A consensus statement on the use of biosimilar medicines in hematology in AustraliaGareth P Gregory, Christine Carrington, Chan Y Cheah, et al.
Internal Medicine Journal|December 20, 2021
Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceColm Keane, Nada Hamad, Allison Barraclough, et al.
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
Internal Medicine Journal|April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphomaMichael Dickinson, Nicole O'Leary, Nada Hamad, et al.
Ejhaem|August 21, 2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at RelapseMark Waltham, Jonathan Wong, Galina Polekhina, et al.
Research and Practice in Thrombosis and Haemostasis|September 1, 2020
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapyHiu Lam Agnes Yuen, Alison Slocombe, Vanessa Heron, et al.
Leukemia & Lymphoma|September 28, 2020
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapyMaciej Tatarczuch, Erin Paul, Michael Gilberston, et al.
British Journal of Haematology|May 16, 2026
Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practiceElizabeth Goodall, Jodie Palmer, Arina Martynchyk, et al.
Pageof 4